You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR CHIAURANIB


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for chiauranib

Trial ID Title Status Sponsor Phase Summary
NCT02122809 ↗ Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed Chipscreen Biosciences, Ltd. Phase 1 The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.
NCT03074825 ↗ Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma Terminated Chipscreen Biosciences, Ltd. Phase 1 Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B(Aurora B)、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
NCT03166891 ↗ Phase Ib Study of Chiauranib in Patients With Ovarian Cancer Completed Chipscreen Biosciences, Ltd. Phase 1/Phase 2 Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B(Aurora B)、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg,QD,PO) works in treating patients with relapsed or refractory ovarian cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
NCT03216343 ↗ Phase Ib Study of Chiauranib in Patients With Small Cell Lung Cancer Unknown status Chipscreen Biosciences, Ltd. Phase 1 Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
NCT03245190 ↗ Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma Completed Chipscreen Biosciences, Ltd. Phase 1/Phase 2 Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
NCT03901118 ↗ Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer Completed Chipscreen Biosciences, Ltd. Phase 2 This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.
NCT03974243 ↗ Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting Chipscreen Biosciences, Ltd. Phase 1/Phase 2 The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib and Chidamide administered orally over a range of doses in patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the pharmacodynamic profile and latent biomarkers accompany with Chiauranib and Chidamide , as well as the relevancy of which and clinical benefit.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for chiauranib

Condition Name

Condition Name
Intervention Trials
Ovarian Cancer 3
Small Cell Lung Cancer 3
Soft Tissue Sarcoma 2
Non-hodgkin's Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Small Cell Lung Carcinoma 5
Lung Neoplasms 4
Ovarian Neoplasms 3
Carcinoma, Ovarian Epithelial 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for chiauranib

Trials by Country

Trials by Country
Location Trials
China 17
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for chiauranib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 2
Phase 2 4
Phase 1/Phase 2 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Recruiting 6
Completed 4
Not yet recruiting 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for chiauranib

Sponsor Name

Sponsor Name
Sponsor Trials
Chipscreen Biosciences, Ltd. 15
Medelis Inc. 1
H & J CRO International, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 18
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.